Document is current

Article History

Received: 26 April 2024

Accepted: 14 October 2024

First Online: 20 October 2024

Declarations

:

: All animal experiments were performed in accordance with relevant guidelines and regulations, either in an approved animal facility at Sangamo Therapeutics France (accredited by the French Ministry of Research, Arrêté n° 4566) according to the APAFIS (“<i>Autorisation de Projet utilisant des Animaux à des Fins Scientifiques</i>”)approved protocol APAFIS#23467-2019101811351116v8 and APAFIS#13779-201802156437559v3 and in compliance with the Guide for the Care and Use of Laboratory Animals. C57BL/6 mice and BALB/c mice were purchased from Charles River (Lyon, France) and SJL mice were purchased from Janvier Labs (Le Genest-saint-Isle, France). Experiments using human samples were performed in accordance with the Declaration of Helsinki and approved by appropriate ethics committees. Peripheral blood mononuclear cells (PBMCs) were obtained from healthy donors following written consent according to protocols approved by the <i>Etablissement Français du sang</i>. PBMCs from RR-MS patients were collected following written consent by Sanguine bio (Woburn, MA), an FDA-registered collection center, from human volunteers who consented under an Institutional Review Board-approved protocol compliant with Code of Federal Regulations Title 21 Part 11.

: Not applicable.

: The authors declare no competing interests.